investors

Investor Overview

Aspen is well positioned in both developing and developed markets – it is the largest pharmaceutical company in Africa, and has an expanding presence in Latin America, Asia, Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics (“CIS”). Aspen is also one of the leading pharmaceutical companies in Australia and is establishing a presence in other developed markets such as the United States of America (“USA”) and Canada.

With an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life, Aspen continues to increase the number of lives benefiting from its products, reaching more than 150 countries across the world.

Aspen released its results for the half-year ended 31 December 2016 on SENS on Thursday, 9 March 2017. This announcement was followed by a presentation to members of the investment community on Friday, 10 March 2017 in Cape Town. The slides accompanying the presentation are available here and on the home page of this website.
A playback of this presentation is available until 30 April 2017. This playback can be accessed by dialing the following number:
Dial in details: +27 11 305 2030
Replay code: 10945

INVESTMENT PROPOSITION

Strong market position


Diversified geographies and product offering


Proven track record


Leverages on local knowledge and expertise

Centralised Group activities facilitate synergies and mitigate pricing pressures


Positive growth drivers


Responsible corporate citizen


Other considerations

INVESTOR CALENDAR

9 March 2017

Interim results announcement

10 March 2017

Interim results presentation in Cape Town.
Click here for the results presentation.
Dial +27 11 305 2030, replay code 10945 to listen to the presentation until 30 April 2017.

30 June 2017

Financial year end

SENS ANNOUNCEMENTS

SHARE PRICE CENTRE

View share price information for Aspen Holdings.

SHARE CODE

APN ISIN: ZAE 000066692

JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.

PRESENTATIONS

PDF 470KB

CAPITAL DISTRIBUTIONS

Delivering double-digit earnings growth to our shareholders for 17 consecutive years

SHAREHOLDER STATISTICS

Analysis of shareholders at 30 June 2016

CORPORATE INFORMATION

All corporate information and contact details

CONTACT DETAILS

Zihle Mgcokoca
+27 31 580 8600
ZMgcokoca@aspenpharma.com